RSS

drug target

UK-based biopharmaceutical company, PhoreMost, has completed a Series A investment round worth £11 million, which will be used to expand operations on the Babraham Research Campus and progress several novel drug targets. more

News

PhoreMost, UK-based biopharmaceutical company, has signed a collaborative agreement with Plexxikon, the small molecule structure-guided R&D centre of Daiichi Sankyo, for the identification of novel drug targets. more

News

Researchers from the University of Glasgow have discovered a potential new drug target for the parasitic disease, toxoplasmosis. more

News